Day: June 22, 2024

Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease risk GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association’s (ADA) 84th Scientific Sessions. “Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of patients with obesity,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “These data add to the differentiated profile of pemvidutide and reinforce...

Casino Group has signed an agreement with Rocca and Auchan Retail France for the sale of its subsidiary Codim 2 Paris, 22 June 2024 Casino Group announces today that it has signed a unilateral purchase agreement for the sale of Codim 2, which operates 4 hypermarkets, 9 supermarkets, 3 cash & carries and 2 drive-throughs in Corsica, with sales of 332 million euros excluding taxes in 2023. As part of the sale, Rocca Group has undertaken to take over all the stores, which will be operated under the Auchan banner, as well as all Codim 2 store and head office employees. Completion of the sale is expected to take place after consultation with employee representative bodies and subject to clearance by the competent competition authorities.          *** This press release has been prepared for information purposes only and should not be construed...

Afrezza®Afrezza® (insulin human) Inhalation Powder.Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% with no increased hypoglycemia compared with 13% with usual care More than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezza®DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 22, 2024 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung...

VANCOUVER, British Columbia, June 21, 2024 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on Thursday, June 20, 2024. A total of 845,972,994 common shares were voted at the Meeting, representing 64.75% of the votes attached to all outstanding common shares. Shareholders voted overwhelmingly in favour of all items of business before the Meeting. The eight director nominees listed in B2Gold’s Management Information Circular (the “Circular”) dated May 8, 2024, were elected as directors of B2Gold to hold office for the ensuing year or until their successors are elected or appointed. Detailed results of the vote for each director are set out below:Name Total...